FIELD: medicine.
SUBSTANCE: invention relates to a method for the treatment of metastatic urothelial cancer, including the administration to a human patient with urothelial cancer of an antibody-drug conjugate (hereinafter – ADC) containing SN-38 conjugated with an anti-Trop-2 antibody hRS7 or its antigen-binding fragment, wherein the specified ADC is administered at a dose of 8 mg/kg or 10 mg/kg, where the specified patient relapsed after one or more previous standard therapy and therapy with checkpoint inhibitors, or was refractory to one or more previous standard therapy and therapy with checkpoint inhibitors before treatment with the specified ADC.
EFFECT: aim of the invention is development of a method for the treatment of urothelial cancer.
17 cl, 9 dwg, 8 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER CHARACTERIZED BY Trop-2 EXPRESSION USING SATSITUZUMAB GOVITECAN AND Rad51 INHIBITOR | 2018 |
|
RU2758234C2 |
| EFFICACY OF CONJUGATES OF ANTI-TROP-2 ANTIBODY WITH DRUG SN-38 FOR THERAPY OF RECURRENT/REFRACTORY TO INHIBITORS OF TUMOR CONTROL POINT | 2017 |
|
RU2725292C2 |
| THERAPEUTIC COMBINATIONS CONTAINING ANTI-FOLR1 IMMUNOCONJUGATES | 2016 |
|
RU2749865C2 |
| ANTI-FOLR1 IMMUNOCONJUGATE APPLICATION SCHEMES | 2014 |
|
RU2801307C1 |
| METHODS OF TREATING USING ANTI-CD123 IMMUNOCONJUGATES | 2019 |
|
RU2816847C2 |
| CREATION OF CONJUGATES OF GD2-SPECIFIC ANTIBODIES AND FRAGMENTS OF GD2-SPECIFIC ANTIBODIES WITH PREPARATIONS | 2019 |
|
RU2733430C1 |
| ANTI-CD79B ANTIBODIES, IMMUNOCONJUGATES AND METHODS FOR THEIR USE | 2019 |
|
RU2791984C2 |
| ANTIBODY-DRUG CONJUGATES AND METHODS OF USING SAID CONJUGATES OF PYRROLOBENZODIAZEPINE | 2016 |
|
RU2736725C1 |
| METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | 2019 |
|
RU2825835C2 |
| ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
